Catalog No.
DHC15803
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Hybridoma growth factor, BSF-2, IFN-beta-2, CDF, IL6, Interleukin-6, IL-6, B-cell stimulatory factor 2, Interferon beta-2, IFNB2, CTL differentiation factor
Concentration
1.05mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P05231
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CNTO 136, CAS: 1194585-53-9
Clone ID
Sirukumab
[Anti-IL-6 : new therapeutic trends], PMID: 28703549
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis, PMID: 27110697
A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis, PMID: 32844378
Absolute Bioavailability and Pharmacokinetic Comparability of Sirukumab Following Subcutaneous Administration by a Prefilled Syringe or an Autoinjector, PMID: 28052588
Antibodies to watch in 2015, PMID: 25484055
Antibodies to watch in 2016, PMID: 26651519
Antibodies to watch in 2017, PMID: 27960628
Comparison of the efficacy and safety of tocilizumab, sarilumab, and sirukumab in comparison with adalimumab as monotherapy in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials, PMID: 34281633
Comparison of the efficacy and tolerability of tocilizumab, sarilumab, and sirukumab in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials, PMID: 29404725
Confirmatory Population Pharmacokinetic Analysis for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin-6, in Patients With Moderately to Severely Active Rheumatoid Arthritis, PMID: 29578578
Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study, PMID: 29483080
Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T), PMID: 29532734
Efficacy and safety of sirukumab in Japanese patients with moderate to severe rheumatoid arthritis inadequately controlled by disease modifying anti-rheumatic drugs: Subgroup analysis of a phase 3 study, PMID: 29336187
Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study, PMID: 28215362
Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review, PMID: 30128641
Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis, PMID: 32033937
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update, PMID: 28264816
Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach, PMID: 26054042
Exposure-Response Modeling Analyses for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin 6, in Patients With Moderately to Severely Active Rheumatoid Arthritis, PMID: 29901815
From mechanism to therapies in systemic lupus erythematosus, PMID: 28118202
IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future, PMID: 25648633
IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab, PMID: 24833786
Insulin Degludec/Liraglutide, PMID: 28804155
Interleukin-6 inhibition in the management of non-infectious uveitis and beyond, PMID: 31523783
Investigating sirukumab for rheumatoid arthritis: 2-year results from the phase III SIRROUND-D study, PMID: 30564449
Joint longitudinal model development: application to exposure-response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumab, PMID: 29961161
Late-Stage Failures of Monoclonal Antibody Drugs: A Retrospective Case Study Analysis, PMID: 31910414
Lessons Learned From the Clinical Trials of Novel Biologics and Small Molecules in Lupus Nephritis, PMID: 26573553
Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE), PMID: 33526709
Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis, PMID: 29186541
Pharmacokinetics and safety of sirukumab following a single subcutaneous administration to healthy Japanese and Caucasian subjects, PMID: 23357841
Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study, PMID: 21392075
Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus, PMID: 23896980
Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis, PMID: 32453485
Profile of sarilumab and its potential in the treatment of rheumatoid arthritis, PMID: 28579757
Rheumatoid arthritis: new monoclonal antibodies, PMID: 29771256
Rheumatoid Arthritis: Sirukumab effective in patients refractory to anti-TNF therapy, PMID: 28250460
Sirukumab : a novel therapy for lupus nephritis?, PMID: 25189410
Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial, PMID: 31018960
Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study, PMID: 28855173
Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018, PMID: 29925278
Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients, PMID: 29514712
Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy, PMID: 24699939
Sirukumab: A Potential Treatment for Mood Disorders?, PMID: 27913990
Sirukumab: a promising therapy for rheumatoid arthritis, PMID: 28374627
Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date, PMID: 27713619
Targeting interleukin-6 for noninfectious uveitis, PMID: 26392750
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer, PMID: 30372844
Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders, PMID: 28098832
Which are the antibodies to watch in 2013?, PMID: 23254906
For research use only. Not for human or drug use.
